The objective of this study is to determine the efficacy of INC424 as assessed by reduction
in spleen volume in patients with primary myelofibrosis (MF), post-polycythemia vera (PV)
MF, or post-essential thrombocythemia (ET) MF. The safety and tolerability of INC424 and the
effects of INC424 on patient reported outcomes and the duration of response as assessed by
reduction in spleen volume will also be assessed.
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Novartis Investigative Site, Jinan 250012, China
Novartis Investigative Site, Shanghai 200025, China
Novartis Investigative Site, Seoul 137-701, Korea, Republic of
Novartis Investigative Site, Kaohsiung 833, Taiwan
Novartis Investigative Site, Taipei 10048, Taiwan
Novartis Investigative Site, Taoyuan 333, Taiwan
Novartis Investigative Site, Nagoya-city, Aichi 466-8560, Japan
Novartis Investigative Site, Beijing, Beijing 100730, China
Novartis Investigative Site, Fukuoka-city, Fukuoka 812-8582, Japan
Novartis Investigative Site, Guangzhou, Guangdong 510030, China
Novartis Investigative Site, Maebashi-city, Gunma 371-8511, Japan
Novartis Investigative Site, Wuhan, Hubei 430030, China
Novartis Investigative Site, Kanazawa, Ishikawa 920-8641, Japan
Novartis Investigative Site, Nanjing, Jiangsu 210029, China
Novartis Investigative Site, Suzhou, Jiangsu 215006, China
Novartis Investigative Site, Seoul, Korea 110 744, Korea, Republic of
Novartis Investigative Site, Seoul, Korea 120-752, Korea, Republic of
Novartis Investigative Site, Seoul, Korea 135-710, Korea, Republic of
Novartis Investigative Site, Tsu-city, Mie 514-8507, Japan
Novartis Investigative Site, Suita-city, Osaka 565-0871, Japan
Novartis Investigative Site, Chengdu, Sichuan 610041, China
Novartis Investigative Site, Bunkyo-ku, Tokyo 113-8655, Japan
Novartis Investigative Site, Shinjuku-ku, Tokyo 160-0023, Japan
Novartis Investigative Site, Shinjuku-ku, Tokyo 160-8582, Japan
Novartis Investigative Site, Hangzhou, Zhejiang 310003, China